# COPD (Chronic Obstructive Pulmonary Disease) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/copd-chronic-obstructive-pulmonary-disease

> 4 upcoming FDA catalysts in COPD (Chronic Obstructive Pulmonary Disease): bgf mdi 320/14.4/9.6 μg (AZN) on Dec 2027 to Mar 2028 (topline data readout); WIN378 (WWB) on Dec 2027 to Mar 2028 (topline data readout); bgf mdi 320/14.4/9.6 μg (AZN) on December 2027 (primary completion); WIN378 (WWB) on December 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 12, 2025 | [Bgf mdi hfo 320/14.4/9.6μg primary completion](https://sec-api.dev/pdufa/bgf-mdi-hfo-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | completed | "NCT06075095 (A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075095)) |
| Dec 2027 to Mar 2028 | [Bgf mdi 320/14.4/9.6 μg topline data readout](https://sec-api.dev/pdufa/bgf-mdi-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT06283966 (A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06283966)) |
| Dec 2027 to Mar 2028 | [WIN378 topline data readout](https://sec-api.dev/pdufa/win378) | WWB | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT07646587 (A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-17 (ESTIMATED); Lead Sponsor Windward Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07646587)) |
| December 2027 | [Bgf mdi 320/14.4/9.6 μg primary completion](https://sec-api.dev/pdufa/bgf-mdi-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT06283966 (A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-03 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06283966)) |
| December 2027 | [WIN378 primary completion](https://sec-api.dev/pdufa/win378) | WWB | COPD (Chronic Obstructive Pulmonary Disease) | scheduled | "NCT07646587 (A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-17 (ESTIMATED); Lead Sponsor Windward Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07646587)) |

## Drugs

- [Bgf mdi hfo 320/14.4/9.6μg](https://sec-api.dev/pdufa/bgf-mdi-hfo-320-14-4) (AZN)
- [Bgf mdi 320/14.4/9.6 μg](https://sec-api.dev/pdufa/bgf-mdi-320-14-4) (AZN)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/copd-chronic-obstructive-pulmonary-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "COPD (Chronic Obstructive Pulmonary Disease) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/copd-chronic-obstructive-pulmonary-disease

```bibtex
@misc{secapidev_indications_copd_chronic_obstructive_pulmonary_disease_20261116,
  title        = {COPD (Chronic Obstructive Pulmonary Disease) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/copd-chronic-obstructive-pulmonary-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_copd_chronic_obstructive_pulmonary_disease_20261116","title":"COPD (Chronic Obstructive Pulmonary Disease) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/copd-chronic-obstructive-pulmonary-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
